sotalol has been researched along with Auricular Flutter in 68 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 9.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| "Immediate pharmacologic therapy for new-onset atrial fibrillation with class III antiarrhythmic drugs (sotalol or amiodarone) improves complication-free 48-hour reversion rates compared with rate control with digoxin." | 9.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "Currently d,l-sotalol is widely used to prevent recurrence of atrial fibrillation and/or atrial flutter, although a randomized dose-response study has not previously been conducted to guide therapy for this indication." | 9.09 | Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. ( Benditt, DG; Browne, K; Chang-Sing, P; Deering, TF; Jin, J; Singh, BN; Williams, JH; Zucker, R, 1999) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 9.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 9.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 9.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| "We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF)." | 7.96 | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study. ( Choi, EK; Kim, JA; Kim, JH; Kwon, TY; Lee, SR; Lee, YE; Oh, S, 2020) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "The records of 120 patients admitted to the hospital for initiation of sotalol therapy were retrospectively reviewed to determine the incidence of significant arrhythmia complications, defined as new or increased ventricular arrhythmias, significant bradycardia or excessive corrected QT (QTc) interval prolongation." | 7.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| "We studied pacing-induced sustained atrial flutter over a 7-day post-surgical period in conscious dogs, alternating analysis of ibutilide (1." | 7.69 | Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. ( Brunden, MN; Buchanan, LV; Gibson, JK; Hsu, CY; LeMay, RJ; Walters, RR, 1996) |
| "This study describes the efficacy of oral sotalol in the treatment and prevention of atrial flutter in children after surgery for congenital heart disease." | 7.69 | Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 6.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| "The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group)." | 6.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 6.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 5.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 5.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 5.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| "These results show that MgCl(2), in addition to sotalol, is not more effective than sotalol alone in the prevention of tachyarrhythmias after CABG." | 5.11 | Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery. ( Beukema, WP; Geertman, H; Sie, HT; van der Starre, PJ; van Rooyen-Butijn, M, 2004) |
| "Immediate pharmacologic therapy for new-onset atrial fibrillation with class III antiarrhythmic drugs (sotalol or amiodarone) improves complication-free 48-hour reversion rates compared with rate control with digoxin." | 5.09 | A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. ( Joseph, AP; Ward, MR, 2000) |
| "Currently d,l-sotalol is widely used to prevent recurrence of atrial fibrillation and/or atrial flutter, although a randomized dose-response study has not previously been conducted to guide therapy for this indication." | 5.09 | Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. ( Benditt, DG; Browne, K; Chang-Sing, P; Deering, TF; Jin, J; Singh, BN; Williams, JH; Zucker, R, 1999) |
| "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven." | 5.08 | Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. ( Ferrick, KJ; Fisher, JD; Gallik, DM; Kim, SG; Roth, JA, 1997) |
| "To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients." | 5.08 | Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. ( Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ, 1998) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 5.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "Oral sotalol is a class III antiarrhythmic commonly used for the maintenance of sinus rhythm in patients with atrial fibrillation (AF)." | 4.31 | Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias. ( Bunch, TJ; Dechand, J; Feuerborn, ML; Freedman, RA; Groh, C; Navaravong, L; Ranjan, R; Steinberg, BA; Torre, M; Vadlamudi, RS; Varela, D, 2023) |
| "We aimed to evaluate the effectiveness and safety of dronedarone versus sotalol in real-world practice in Asian patients with atrial fibrillation (AF)." | 3.96 | Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study. ( Choi, EK; Kim, JA; Kim, JH; Kwon, TY; Lee, SR; Lee, YE; Oh, S, 2020) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months." | 3.80 | Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents. ( Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D, 2014) |
| "To determine how well dofetilide and Betapace AF (sotalol, approved solely for atrial fibrillation and atrial flutter), with their detailed dosing and monitoring guidelines for safety, were accepted into clinical practice during the 2 calendar years after their introduction." | 3.72 | New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance. ( Kramer, JM; LaPointe, NM; Pamer, CA, 2003) |
| "The records of 120 patients admitted to the hospital for initiation of sotalol therapy were retrospectively reviewed to determine the incidence of significant arrhythmia complications, defined as new or increased ventricular arrhythmias, significant bradycardia or excessive corrected QT (QTc) interval prolongation." | 3.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| "This study describes the efficacy of oral sotalol in the treatment and prevention of atrial flutter in children after surgery for congenital heart disease." | 3.69 | Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "We studied pacing-induced sustained atrial flutter over a 7-day post-surgical period in conscious dogs, alternating analysis of ibutilide (1." | 3.69 | Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. ( Brunden, MN; Buchanan, LV; Gibson, JK; Hsu, CY; LeMay, RJ; Walters, RR, 1996) |
| "One hundred nine patients with recurrent episodes of symptomatic atrial fibrillation or flutter, or both, who had failed one to five previous antiarrhythmic drug trials were treated with propafenone and, subsequently, sotalol if atrial fibrillation recurred." | 3.68 | Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. ( Antman, EM; Beamer, AD; Cantillon, C; Friedman, PL; McGowan, N, 1990) |
| "Neonatal tachyarrhythmia was observed in 31." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "The occurrence of paroxysmal atrial fibrillation is documented by transtelephonic ECG monitoring." | 2.69 | [Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians]. ( Koch, HP; Lüderitz, B; Meinertz, T; Patten, M; Sonntag, F, 1999) |
| "Fetal hydrops was seen in 20 patients; 17 received maternal therapy, 2 were delivered and 1 was not treated because it had a severe nontreatable cardiac malformation." | 2.69 | Atrial flutter in the perinatal age group: diagnosis, management and outcome. ( Benatar, AA; Brenner, JI; Kleinman, CS; Lisowski, LA; Meijboom, EJ; Soyeur, DJ; Stoutenbeek, P; Verheijen, PM, 2000) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 2.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| "The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group)." | 2.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Amiodarone has a conversion rate in atrial fibrillation of up to 80%." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "With a probability of success of 90%, a recurrence rate of 5% to 15%, and few complications, catheter ablation emerges as the best treatment of recurrent, symptomatic flutter." | 2.41 | Management of atrial flutter. ( Aass, H; Kongsgaard, E, 2000) |
| "Both amiodarone and sotalol were more effective than placebo treatment in reducing the incidence of postoperative AFF." | 2.41 | Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis. ( Lenz, TL; Mohiuddin, SM; Mooss, AN; Wurdeman, RL, 2002) |
| "Fetal hydrops was present in six patients (five with SVT, one with AF)." | 1.39 | Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. ( Freund, MW; Manten, GT; Oudijk, MA; Pistorius, L; ter Heide, H; van der Heijden, LB, 2013) |
| "If the fetal atrial flutter is resistant to these therapies, a combination of other congenital cardiac diseases or organic abnormalities should be considered." | 1.33 | Fetal atrial flutter: a case report and experience of sotalol treatment. ( Chiu, TH; Ho, M; Huang, LC; Hung, YC; Lee, CC; Wu, TH, 2006) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | 1.31 | [Ion channels and arrhythmias]. ( Borchard, U; Hafner, D, 2000) |
| "Atrial tachyarrhythmias were induced by right atrial burst pacing." | 1.30 | Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. ( Fries, R; Heisel, A; Jung, J; Ozbek, C; Schieffer, H; Sen, S; Stopp, M, 1997) |
| " Conversion to sinus rhythm was achieved in 16 out of 22 hemodynamically stable children with a dosage of 4." | 1.30 | Sotalol for atrial tachycardias after surgery for congenital heart disease. ( Beaufort-Krol, GC; Bink-Boelkens, MT, 1997) |
| "d-Sotalol was effective in terminating atrial re-entry in this model." | 1.29 | Multiple modes of termination of re-entrant excitation around an anatomic barrier in the canine atrium during the action of d-sotalol. ( Boyden, PA; Graziano, JN, 1993) |
| "D-sotalol was effective in terminating atrial reentry in this model." | 1.29 | Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. ( Boyden, PA; Graziano, JN, 1993) |
| "Sotalol may inhibit IK." | 1.29 | Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms. ( Hara, Y; Masuda, Y; Mori, K; Nakaya, H; Saito, T, 1995) |
| " Mean dosage was 4." | 1.29 | [Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias]. ( Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1994) |
| "Sotalol is a beta-blocker with class III antiarrhythmic properties that has recently been used in children for the treatment of supraventricular and ventricular arrhythmias." | 1.28 | Electrophysiologic effects of sotalol on the immature mammalian heart. ( Chartrand, C; Davignon, A; Ducharme, G; Fournier, A; Houyel, L, 1992) |
| "2% after intravenous d-sotalol, but no adverse symptoms developed." | 1.28 | Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. ( Bigger, JT; Kidwell, GA; Reiffel, JA; Sahar, DI; Squatrito, A, 1989) |
| " Twenty-nine patients with supraventricular tachyarrhythmias were treated on 31 occasions to determine the effective therapeutic dosage and optimal method of administration." | 1.27 | Sotalol infusion in the treatment of supraventricular tachyarrhythmias. ( Harte, M; Horgan, JH; Teo, KK, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (11.76) | 18.7374 |
| 1990's | 27 (39.71) | 18.2507 |
| 2000's | 20 (29.41) | 29.6817 |
| 2010's | 10 (14.71) | 24.3611 |
| 2020's | 3 (4.41) | 2.80 |
| Authors | Studies |
|---|---|
| Feuerborn, ML | 1 |
| Dechand, J | 1 |
| Vadlamudi, RS | 1 |
| Torre, M | 1 |
| Freedman, RA | 1 |
| Groh, C | 1 |
| Navaravong, L | 1 |
| Ranjan, R | 1 |
| Varela, D | 1 |
| Bunch, TJ | 1 |
| Steinberg, BA | 1 |
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Etheridge, SP | 1 |
| Asaki, SY | 1 |
| Lee, SR | 1 |
| Choi, EK | 1 |
| Kim, JH | 1 |
| Kim, JA | 1 |
| Kwon, TY | 1 |
| Lee, YE | 1 |
| Oh, S | 1 |
| Shozu, M | 1 |
| Strasburger, JF | 1 |
| Leslie, SD | 1 |
| Guerra, F | 1 |
| Hohnloser, SH | 1 |
| Kowey, PR | 1 |
| Crijns, HJ | 2 |
| Aliot, EM | 1 |
| Radzik, D | 1 |
| Roy, D | 1 |
| Connolly, S | 1 |
| Capucci, A | 1 |
| Borchetta, K | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Rao, SO | 1 |
| Boramanand, NK | 1 |
| Burton, DA | 1 |
| Perry, JC | 1 |
| Zakrzewska-Koperska, J | 1 |
| Urbanek, P | 1 |
| Szufladowicz, E | 1 |
| Bodalski, R | 1 |
| Szumowski, Ł | 1 |
| Maryniak, A | 1 |
| Walczak, F | 1 |
| Armentano, RA | 1 |
| Schmidt, MK | 1 |
| Maisenbacher, HW | 1 |
| Shah, A | 1 |
| Moon-Grady, A | 1 |
| Bhogal, N | 1 |
| Collins, KK | 1 |
| Tacy, T | 1 |
| Brook, M | 1 |
| Hornberger, LK | 1 |
| van der Heijden, LB | 1 |
| Oudijk, MA | 2 |
| Manten, GT | 1 |
| ter Heide, H | 1 |
| Pistorius, L | 1 |
| Freund, MW | 1 |
| Jalil, E | 1 |
| Mensour, B | 1 |
| Vinet, A | 1 |
| Kus, T | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Trappe, HJ | 1 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| LaPointe, NM | 1 |
| Pamer, CA | 1 |
| Kramer, JM | 1 |
| Khan, IA | 2 |
| Geertman, H | 1 |
| van der Starre, PJ | 1 |
| Sie, HT | 1 |
| Beukema, WP | 1 |
| van Rooyen-Butijn, M | 1 |
| Scharf, C | 1 |
| Wu, TH | 1 |
| Huang, LC | 1 |
| Ho, M | 1 |
| Lee, CC | 1 |
| Chiu, TH | 1 |
| Hung, YC | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Paul, T | 1 |
| Lehmann, C | 1 |
| Pfammatter, JP | 1 |
| Kallfelz, HC | 1 |
| Mori, K | 1 |
| Hara, Y | 1 |
| Saito, T | 1 |
| Masuda, Y | 1 |
| Nakaya, H | 1 |
| Sung, RJ | 1 |
| Tan, HL | 1 |
| Karagounis, L | 1 |
| Hanyok, JJ | 1 |
| Falk, R | 1 |
| Platia, E | 1 |
| Das, G | 1 |
| Hardy, SA | 1 |
| Daubert, C | 1 |
| Mabo, P | 1 |
| Gras, D | 1 |
| Leclercq, C | 1 |
| Jacquet, L | 1 |
| Evenepoel, M | 1 |
| Marenne, F | 1 |
| Evrard, P | 1 |
| Verhelst, R | 1 |
| Dion, R | 1 |
| Goenen, M | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Boyden, PA | 2 |
| Graziano, JN | 2 |
| Buchanan, LV | 1 |
| LeMay, RJ | 1 |
| Walters, RR | 1 |
| Hsu, CY | 1 |
| Brunden, MN | 1 |
| Gibson, JK | 1 |
| Fonteyne, W | 1 |
| Bauwens, A | 1 |
| Jordaens, L | 1 |
| Beaufort-Krol, GC | 2 |
| Bink-Boelkens, MT | 2 |
| Heisel, A | 2 |
| Jung, J | 2 |
| Fries, R | 1 |
| Stopp, M | 1 |
| Sen, S | 1 |
| Schieffer, H | 2 |
| Ozbek, C | 1 |
| Gallik, DM | 1 |
| Kim, SG | 1 |
| Ferrick, KJ | 1 |
| Roth, JA | 1 |
| Fisher, JD | 1 |
| Neuzner, J | 1 |
| Fröhlig, G | 1 |
| Tai, CT | 1 |
| Chen, SA | 1 |
| Chiang, CE | 1 |
| Lee, SH | 1 |
| Ueng, KC | 1 |
| Wen, ZC | 1 |
| Huang, JL | 1 |
| Chen, YJ | 1 |
| Yu, WC | 1 |
| Feng, AN | 1 |
| Chiou, CW | 1 |
| Chang, MS | 1 |
| Basta, M | 1 |
| Klein, GJ | 1 |
| Yee, R | 1 |
| Krahn, A | 1 |
| Lee, J | 1 |
| Chung, MK | 1 |
| Schweikert, RA | 1 |
| Wilkoff, BL | 1 |
| Niebauer, MJ | 1 |
| Pinski, SL | 1 |
| Trohman, RG | 1 |
| Kidwell, GA | 2 |
| Jaeger, FJ | 1 |
| Morant, VA | 1 |
| Miller, DP | 1 |
| Tchou, PJ | 1 |
| Marcus, FI | 1 |
| Vos, MA | 1 |
| Golitsyn, SR | 1 |
| Stangl, K | 1 |
| Ruda, MY | 1 |
| Van Wijk, LV | 1 |
| Harry, JD | 1 |
| Perry, KT | 1 |
| Touboul, P | 1 |
| Steinbeck, G | 1 |
| Wellens, HJ | 1 |
| Patten, M | 1 |
| Koch, HP | 1 |
| Sonntag, F | 1 |
| Meinertz, T | 1 |
| Benditt, DG | 1 |
| Williams, JH | 1 |
| Jin, J | 1 |
| Deering, TF | 1 |
| Zucker, R | 1 |
| Browne, K | 1 |
| Chang-Sing, P | 1 |
| Singh, BN | 2 |
| Lisowski, LA | 1 |
| Verheijen, PM | 1 |
| Benatar, AA | 1 |
| Soyeur, DJ | 1 |
| Stoutenbeek, P | 2 |
| Brenner, JI | 1 |
| Kleinman, CS | 1 |
| Meijboom, EJ | 2 |
| Borchard, U | 1 |
| Hafner, D | 1 |
| Naccarelli, GV | 1 |
| Dell'Orfano, JT | 1 |
| Wolbrette, DL | 1 |
| Patel, HM | 1 |
| Luck, JC | 1 |
| Joseph, AP | 1 |
| Ward, MR | 1 |
| Kongsgaard, E | 1 |
| Aass, H | 1 |
| Cosío, FG | 1 |
| Ambachtsheer, EB | 1 |
| Wurdeman, RL | 1 |
| Mooss, AN | 1 |
| Mohiuddin, SM | 1 |
| Lenz, TL | 1 |
| Houyel, L | 1 |
| Fournier, A | 1 |
| Ducharme, G | 1 |
| Chartrand, C | 1 |
| Davignon, A | 1 |
| Feld, GK | 2 |
| Shahandeh-Rad, F | 1 |
| Van Gelder, IC | 1 |
| Van Gilst, WH | 1 |
| Hillege, H | 1 |
| Gosselink, AM | 1 |
| Lie, KI | 1 |
| Antman, EM | 1 |
| Beamer, AD | 1 |
| Cantillon, C | 1 |
| McGowan, N | 1 |
| Friedman, PL | 1 |
| Sahar, DI | 1 |
| Reiffel, JA | 1 |
| Bigger, JT | 1 |
| Squatrito, A | 1 |
| Gautam, CS | 1 |
| Lal, R | 1 |
| Pandhi, P | 1 |
| Sharma, PL | 1 |
| Ramsdale, DR | 1 |
| Peterson, C | 1 |
| Venkatesh, N | 1 |
| Campbell, TJ | 1 |
| Gavaghan, TP | 1 |
| Morgan, JJ | 1 |
| Teo, KK | 1 |
| Harte, M | 1 |
| Horgan, JH | 1 |
| Prakash, R | 1 |
| Parmley, WW | 1 |
| Allen, HN | 1 |
| Matloff, JM | 1 |
| Gettes, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation Analysis and Kinetics of IV Sotalol[NCT05247320] | 167 participants (Actual) | Observational | 2022-02-04 | Completed | |||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for sotalol and Auricular Flutter
| Article | Year |
|---|---|
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
Atrial stunning: basics and clinical considerations.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Atrial Functi | 2003 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Humans; | 1993 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Calcium Channel Blockers; Digoxin; El | 1997 |
Risks of initiating therapy with sotalol for treatment of atrial fibrillation.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flu | 1998 |
Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cost-Benefit An | 2000 |
Management of atrial flutter.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Catheter Ablation; Electrophysiologic Techniques, C | 2000 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Artery Bypas | 2002 |
Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Appendage; Atrial Fibrillation; Atrial | 2002 |
Beta adrenergic blocking drugs in the treatment of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Alprenolol; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillatio | 1970 |
13 trials available for sotalol and Auricular Flutter
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Child; Heart Defect | 2009 |
Magnesium in addition to sotalol does not influence the incidence of postoperative atrial tachyarrhythmias after coronary artery bypass surgery.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Coronary Artery | 2004 |
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1995 |
Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardia | 1994 |
Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Hemodynamics; Humans; Male; Midd | 1997 |
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1998 |
[Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT Study. Executive committee of the investigators representing trial physicians].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Doubl | 1999 |
Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disease-Free Survival; Dose-Response Re | 1999 |
Atrial flutter in the perinatal age group: diagnosis, management and outcome.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Digoxin; Echocardiography, Doppler; Electric Countershock; E | 2000 |
A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
Topics: Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; | 2000 |
Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Clinical Trials as Topic; Digoxin; Diso | 1985 |
41 other studies available for sotalol and Auricular Flutter
| Article | Year |
|---|---|
Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Female; H | 2023 |
An Exciting New Tool in the Electrophysiologist's Toolbox, Intravenous Sotalol: Faster, Safer, Better?
Topics: Atrial Flutter; Humans; Sotalol; Tachycardia, Supraventricular | 2020 |
Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study.
Topics: Aged; Anti-Arrhythmia Agents; Asian People; Atrial Fibrillation; Atrial Flutter; Cause of Death; Dro | 2020 |
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Re: Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. L. B. van der Heijden, M. A. Oudijk, G. Manten, H. ter Heide, L. Pistorius and M. W. Freund. Ultrasound Obstet Gynecol 2013; 42: 285-293.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Female; Fetal Diseases; Humans; Pregnancy; Sotalol; Tachycar | 2013 |
Sotalol-associated cardiogenic shock in a patient with asymptomatic transient rate-related cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Asymptomatic Diseases; Atrial Flutter; Humans; Male; Shock, Cardiogeni | 2013 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Droned | 2014 |
Case 1: Wheezing Unresponsive to Bronchodilators in a 4-month-old Boy.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Bronchiolitis; Bronchodilator Agents; Diagnosis, Differentia | 2015 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
[Next cardioversion or RF ablation in professional driver with recurrent typical atrial flutter and MAS syndromes].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Automobile Driving; Catheter Ablation; Electrocardiog | 2009 |
ECG of the Month. Atrial flutter.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Dog Diseases; Dogs; Electrocardiography; Male; Sota | 2010 |
Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias.
Topics: Abortion, Induced; Anti-Arrhythmia Agents; Atrial Flutter; Bradycardia; Catheter Ablation; Digoxin; | 2012 |
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Female; Fetal Diseases; Follow-Up Studies; | 2013 |
Excitable gap composition in the presence of antiarrhythmic drugs in common human atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Female; Heart Co | 2003 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Databases, Factual; Drug Prescriptions; | 2003 |
Fetal atrial flutter: a case report and experience of sotalol treatment.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Delivery, | 2006 |
[Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias].
Topics: Administration, Oral; Adolescent; Adult; Atrial Flutter; Atrioventricular Node; Cardiac Complexes, P | 1994 |
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutt | 1995 |
Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Atrial Function; Dogs; Endocardium; Heart Atria; He | 1993 |
Multiple modes of termination of re-entrant excitation around an anatomic barrier in the canine atrium during the action of d-sotalol.
Topics: Animals; Atrial Flutter; Atrial Function, Right; Cardiac Pacing, Artificial; Dogs; Electrocardiograp | 1993 |
Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Cross-Over Studies; Dogs; Electrocardiography; Infu | 1996 |
Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine.
Topics: Antimalarials; Atrial Flutter; Digitoxin; Drug Therapy, Combination; Heart Conduction System; Humans | 1996 |
Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Flutter; Child; Child, Preschool; Heart Defects, Congenit | 1997 |
Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing | 1997 |
Sotalol for atrial tachycardias after surgery for congenital heart disease.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bradycardi | 1997 |
[Biatrial stimulation in therapy of paroxysmal atrial tachycardia: a case report].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrial Function; Combined Modalit | 1997 |
Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Catheterization; Electrophy | 1997 |
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia | 1998 |
[Ion channels and arrhythmias].
Topics: Action Potentials; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrial Fib | 2000 |
Oral d,l-sotalol in atrial fibrillation and/or flutter.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation | 2000 |
Electrophysiologic effects of sotalol on the immature mammalian heart.
Topics: Animals; Animals, Newborn; Atrial Flutter; Atrioventricular Node; Cardiac Pacing, Artificial; Dogs; | 1992 |
Mechanism of double potentials recorded during sustained atrial flutter in the canine right atrial crush-injury model.
Topics: Action Potentials; Animals; Atrial Flutter; Atrial Function; Cardiac Pacing, Artificial; Dogs; Elect | 1992 |
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter.
Topics: Actuarial Analysis; Aged; Amiodarone; Analysis of Variance; Atrial Fibrillation; Atrial Flutter; Chr | 1991 |
Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Data Interpretation, Statistical; Drug Administrat | 1990 |
Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; | 1989 |
Differential effect of some antiarrhythmic drugs in right- or left-sided aconitine-induced experimental atrial arrhythmias.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dogs; Female; Male; | 1987 |
Successful termination of combined rapid atrial flutter/fibrillation and ventricular tachycardia by intravenous sotalol.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Infusions | 1987 |
Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
Topics: Animals; Atrial Flutter; Cardiac Pacing, Artificial; Dogs; Drug Evaluation; Electrocardiography; Ele | 1986 |
Sotalol infusion in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Female; Humans; Male; Middle | 1985 |
Effect of Sotalol on clinical arrhythmias.
Topics: Administration, Oral; Aged; Amino Alcohols; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1972 |